NasdaqCM - Delayed Quote USD

Atossa Therapeutics, Inc. (ATOS)

Compare
1.0100 +0.0499 (+5.20%)
At close: January 3 at 4:00:02 PM EST
1.0299 +0.02 (+1.97%)
After hours: January 3 at 7:59:19 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ATOS

Recent News: ATOS

View More
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Zacks 16 days ago
Atossa Therapeutics to present poster on Z-endoxifen at SABCS

Atossa Therapeutics to present poster on Z-endoxifen at SABCS
TipRanks 23 days ago
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
GlobeNewswire 24 days ago
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
GlobeNewswire 25 days ago
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
GlobeNewswire 26 days ago
Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research
GlobeNewswire 27 days ago
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
GlobeNewswire last month
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
GlobeNewswire last month
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?

Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?
Zacks last month
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire last month
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
GlobeNewswire last month
View More

Related Tickers

CERO CERo Therapeutics Holdings, Inc.
0.0582
-4.59%
 
OCGN Ocugen, Inc.
0.8945
-0.61%
 
TNXP Tonix Pharmaceuticals Holding Corp.
0.3100
-1.27%
 
SLS SELLAS Life Sciences Group, Inc.
1.0800
+0.93%
 
IMNN Imunon, Inc.
1.0200
-2.86%
 
BLRX BioLineRx Ltd.
0.2738
+7.12%
 
JAGX Jaguar Health, Inc.
1.1500
+5.50%
 
CKPT Checkpoint Therapeutics, Inc.
3.6500
+10.94%
 
NRXP NRx Pharmaceuticals, Inc.
2.6900
-10.03%
 
CTXR Citius Pharmaceuticals, Inc.
3.9800
+2.58%